NCT03314181 trial: what clinicians have said so far
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
- NCT03314181 ↗
- Active, not recruiting
- AbbVie
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT03314181 (venetoclax plus daratumumab plus dexamethasone; venetoclax plus daratumumab plus dexamethasone plus bortezomib in relapsed or refractory multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03314181 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Dexamethasone; Daratumumab; Venetoclax; Bortezomib
- Arms
- Arm A, Part 1a: VenDd Dose Escalation · Experimental
- Arm B, Part 1b: VenDd Dose Expansion · Experimental
- Arm D, Part 2a: VenDVd Dose Escalation · Experimental
- Arm E, Part 2b: VenDVd Dose Expansion · Experimental
- Arm F: VenDd Dose Expansion · Experimental
- Arm G: VenDd Dose Expansion · Experimental
- Arm H: DVd Dose · Active comparator
- Enrollment
- 156
- Primary outcomes
- Overall Response Rate (ORR)
- Very Good Partial Response or Better Response Rate (VGPR)
- Complete Response (CR) or Better Rate
- Time to Response (TTR)
- Duration of Response (DOR)
- Time to Progression (TTP)
- Progression-Free Survival (PFS)
- Overall Survival (OS)
- Sponsor
- AbbVie with Janssen Research & Development, LLC
- Start
- Apr 2, 2018
- Primary completion
- May 2031 (estimated)
- Results posted
- No
- Registry record
- NCT03314181 · updated Aug 14, 2025
Publications
linked from the registry- Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ, Plesner T, Moreau P, Gibbs SD, Coppola S, Yang X, Al Masud A, Ross JA, Bueno O, Kaufman JL. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). J Clin Oncol. 2021 Nov 10;39(32):3602-3612. doi: 10.1200/JCO.21.00443. Epub 2021 Aug 13. PubMed 34388020